Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

This study has been completed.
Information provided by:
YM BioSciences Identifier:
First received: January 11, 2008
Last updated: July 4, 2011
Last verified: July 2011
This is a phase 2, single-arm, multi-center study, with a safety review component, designed to evaluate the efficacy and safety of nimotuzumab in approximately 44 patients with recurrent diffuse intrinsic pontine glioma (DIPG) following one previous regimen for their disease. Patients must be diagnosed with radiologically verified recurrent diffuse intrinsic pontine glioma that is measurable in at least two dimensions. Patients are eligible without histologic confirmation. Treatment regimen will consist of two phases-induction and consolidation.

Condition Intervention Phase
Recurrent Diffuse Pontine Gliomas
Biological: nimotuzumab (anti EGFR humanized monoclonal antibody)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma

Resource links provided by NLM:

Further study details as provided by YM BioSciences:

Primary Outcome Measures:
  • To determine the objective response rate [ Time Frame: To determine response rate on week 18 ]

Secondary Outcome Measures:
  • To evaluate the safety profile of single agent nimotuzumab in this population [ Time Frame: safety will be evaluated after each study drug administration ]

Enrollment: 44
Study Start Date: October 2007
Study Completion Date: December 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single arm Biological: nimotuzumab (anti EGFR humanized monoclonal antibody)
150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.


Ages Eligible for Study:   3 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed written informed consent
  • Patients with recurrent, diffuse intrinsic pontine gliomas
  • Patients should have had 2 of the following 3 neurological symptoms: cranial nerve deficit, long tract signs, ataxia and a onset prior to initial diagnosis < 6 months.
  • Evidence of disease progression
  • Have a Lansky or Karnofsky Performance Status of > 40
  • Be between the age >3 years to < 18 years of age
  • Have a tumor that is measurable radiologically
  • For female patients of childbearing age: presence of a negative pregnancy test within 7 days prior to day 0.
  • Use of effective contraception
  • Adequate hematological, renal, and hepatic function

Exclusion Criteria:

  • A history of prior use of EGFR-targeting agents (monoclonal antibodies, tyrosine kinase inhibitors)
  • More than one line of treatment
  • Patients with disseminated disease are not eligible
  • Had radiation therapy completed within 12 weeks of enrollment
  • Previous chemotherapy completed < 2 weeks prior to enrollment
  • If female, is pregnant or lactating
  • Has other existing serious medical conditions
  • Has any condition, therapy, or medical condition, which, in the opinion of the attending physician could represent a risk for the patient or adversely affect the study objectives
  • Is currently taking or planning to take other investigational drugs during the study
  • Known contraindications against antibodies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00600054

United States, Colorado
Children's Hospital/University of Colorado
Denver, Colorado, United States, 80045
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Florida
University of Florida Shands Cancer Center
Gainesville, Florida, United States, 32611
United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614-3394
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Baltimore, Maryland, United States, 21287
United States, New York
NYU Medical Center, Hassenfeld Clinic
New York, New York, United States, 10016
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
University of Rochester Medical Center, Strong Memorial Hospital
Rochester, New York, United States, 10016
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-6310
United States, Texas
The University of Texas/M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada, T3B 6A8
Canada, Ontario
The Hospital For Sick Children
Toronto, Ontario, Canada, M5G 1X8
The Chaim Sheba Medical Center
Tel-Hashomer, Israel, 52621
Sponsors and Collaborators
YM BioSciences
Principal Investigator: Eric Bouffet, MD The Hospital for Sick Children
Principal Investigator: Ute Bartels, MD The Hospital for Sick Children
Principal Investigator: Sylvain Baruchel, MD The Hospital for Sick Children
  More Information

Responsible Party: Wendy Chapman, Vice President, Clinical Operations, YM BioSciences Inc. Identifier: NCT00600054     History of Changes
Other Study ID Numbers: YMB1000-013
Study First Received: January 11, 2008
Last Updated: July 4, 2011

Keywords provided by YM BioSciences:
Diffuse intrinsic pontine glioma
Common Terminology Criteria
Epidermal Growth factor receptor
Human antihuman antibody
monoclonal antibody
Informed Consent Form

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on April 21, 2017